NASDAQ:PLRX Pliant Therapeutics (PLRX) Stock Price, News & Analysis $12.87 -0.48 (-3.60%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$12.57▼$13.6450-Day Range$10.52▼$14.3552-Week Range$10.29▼$19.62Volume181,606 shsAverage Volume461,994 shsMarket Capitalization$776.40 millionP/E RatioN/ADividend YieldN/APrice Target$41.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Pliant Therapeutics alerts: Email Address Pliant Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside225.0% Upside$41.83 Price TargetShort InterestBearish12.17% of Shares Sold ShortDividend StrengthN/ASustainability-0.73Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$804,530 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.69) to ($4.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.04 out of 5 starsMedical Sector328th out of 910 stocksPharmaceutical Preparations Industry141st out of 426 stocks 3.5 Analyst's Opinion Consensus RatingPliant Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePliant Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Pliant Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.17% of the outstanding shares of Pliant Therapeutics have been sold short.Short Interest Ratio / Days to CoverPliant Therapeutics has a short interest ratio ("days to cover") of 12.4, which indicates bearish sentiment.Change versus previous monthShort interest in Pliant Therapeutics has recently increased by 4.26%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPliant Therapeutics does not currently pay a dividend.Dividend GrowthPliant Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePliant Therapeutics has received a 74.73% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Pliant Therapeutics is -0.73. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Pliant Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for PLRX on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows3 people have added Pliant Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pliant Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $804,530.00 in company stock.Percentage Held by InsidersOnly 6.40% of the stock of Pliant Therapeutics is held by insiders.Percentage Held by Institutions97.30% of the stock of Pliant Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pliant Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Pliant Therapeutics are expected to decrease in the coming year, from ($3.69) to ($4.04) per share.Price to Book Value per Share RatioPliant Therapeutics has a P/B Ratio of 1.63. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pliant Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Pliant Therapeutics Stock (NASDAQ:PLRX)Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.Read More PLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PLRX Stock News HeadlinesSeptember 5 at 10:54 PM | markets.businessinsider.comOppenheimer Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)August 28, 2024 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 28, 2024 | globenewswire.comPliant Therapeutics to Participate in Upcoming Investor EventsAugust 28, 2024 | americanbankingnews.comPliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Consensus Recommendation of "Buy" from AnalystsAugust 26, 2024 | finance.yahoo.comPliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024August 26, 2024 | globenewswire.comPliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024August 18, 2024 | finance.yahoo.comPLRX Sep 2024 12.500 put (PLRX240920P00012500)September 7, 2024 | Crypto 101 Media (Ad)Perfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying with both fists. They know it's only a matter of time before another bull run. Now, Crypto Insiders Are Scooping up Lesser-Known Coins and Making Serious BankAugust 14, 2024 | uk.finance.yahoo.comPliant Therapeutics Inc. (US7291391057.SG)August 12, 2024 | markets.businessinsider.comBullish Outlook on Pliant Therapeutics: Advancing Pipeline and Regulatory Confidence Fuel Buy RatingAugust 9, 2024 | seekingalpha.comPLRX Pliant Therapeutics, Inc.August 8, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Pliant Therapeutics (PLRX)August 8, 2024 | markets.businessinsider.comPLRX Stock Earnings: Pliant Therapeutics Misses EPS for Q2 2024August 7, 2024 | finance.yahoo.comPliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | globenewswire.comPliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth ConferenceJune 24, 2024 | investorplace.com7 Biotech Stocks to Buy on the Dip: June 2024June 13, 2024 | globenewswire.comPliant Therapeutics Announces Appointment of Steve Krognes to Board of DirectorsSee More Headlines Receive PLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLRX CUSIPN/A CIK1746473 Webpliantrx.com Phone650-481-6770FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$41.83 High Stock Price Target$45.00 Low Stock Price Target$38.00 Potential Upside/Downside+225.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,340,000.00 Net MarginsN/A Pretax Margin-68,847.98% Return on Equity-41.05% Return on Assets-36.04% Debt Debt-to-Equity Ratio0.08 Current Ratio14.47 Quick Ratio14.47 Sales & Book Value Annual Sales$1.58 million Price / Sales491.39 Cash FlowN/A Price / Cash FlowN/A Book Value$7.91 per share Price / Book1.63Miscellaneous Outstanding Shares60,326,000Free Float56,465,000Market Cap$776.40 million OptionableOptionable Beta1.14 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesDr. Bernard Coulie M.B.A. (Age 57)M.D., Ph.D., President, CEO & Director Comp: $996.97kDr. Keith Lamont Cummings M.B.A. (Age 47)M.D., Chief Financial Officer Comp: $684.14kMr. Mike Ouimette J.D. (Age 51)General Counsel & Corporate Secretary Comp: $606.03kMr. Johannes P. Hull (Age 49)Chief Business Officer Comp: $602.51kDr. Éric Lefebvre M.D. (Age 60)Chief Medical Officer Comp: $734.41kDr. Rik DerynckScientific Founder & Member of Scientific Advisory BoardMr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Bill DeGrado Ph.D.Scientific Founder & Member of Scientific Advisory BoardMr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Craig D. MuirInterim Chief Technology OfficerMore ExecutivesKey CompetitorsAnnexonNASDAQ:ANNXFibroGenNASDAQ:FGENHUTCHMEDNASDAQ:HCMIovance BiotherapeuticsNASDAQ:IOVAXenon PharmaceuticalsNASDAQ:XENEView All CompetitorsInsiders & InstitutionsAlgert Global LLCBought 52,912 shares on 8/16/2024Ownership: 0.115%The Manufacturers Life Insurance Company Bought 1,191 shares on 8/15/2024Ownership: 0.137%Deerfield Management Company L.P. Series CBought 11,678 shares on 8/15/2024Ownership: 0.019%Squarepoint Ops LLCBought 80,475 shares on 8/14/2024Ownership: 0.132%ProShare Advisors LLCSold 3,110 shares on 8/14/2024Ownership: 0.019%View All Insider TransactionsView All Institutional Transactions PLRX Stock Analysis - Frequently Asked Questions How have PLRX shares performed this year? Pliant Therapeutics' stock was trading at $18.11 at the beginning of 2024. Since then, PLRX stock has decreased by 28.9% and is now trading at $12.87. View the best growth stocks for 2024 here. How were Pliant Therapeutics' earnings last quarter? Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by $0.07. When did Pliant Therapeutics IPO? Pliant Therapeutics (PLRX) raised $90 million in an initial public offering on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler served as the underwriters for the IPO and Needham & Company was co-manager. Who are Pliant Therapeutics' major shareholders? Pliant Therapeutics' top institutional shareholders include First Light Asset Management LLC (5.59%), Great Point Partners LLC (4.34%), Candriam S.C.A. (1.38%) and Dimensional Fund Advisors LP (0.51%). Insiders that own company stock include Bernard Coulie, Keith Lamont Cummings, Eric Lefebvre, Hans Hull and Mike Ouimette. View institutional ownership trends. How do I buy shares of Pliant Therapeutics? Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Pliant Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT) and Archer-Daniels-Midland (ADM). This page (NASDAQ:PLRX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pliant Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pliant Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PLRX Stock Alerts